Gongwin Biopharm Holdings Statistics

Total Valuation

Gongwin Biopharm Holdings has a market cap or net worth of TWD 14.41 billion. The enterprise value is 12.09 billion.

Market Cap	14.41B
Enterprise Value	12.09B

Important Dates

The last earnings date was Thursday, November 28, 2024.

Earnings Date	Nov 28, 2024
Ex-Dividend Date	n/a

Share Statistics

Gongwin Biopharm Holdings has 127.51 million shares outstanding. The number of shares has increased by 3.98% in one year.

Current Share Class	n/a
Shares Outstanding	127.51M
Shares Change (YoY)	+3.98%
Shares Change (QoQ)	+6.05%
Owned by Insiders (%)	24.03%
Owned by Institutions (%)	0.05%
Float	59.10M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
PB Ratio	4.33
P/TBV Ratio	4.52
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-117.42
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-42.97

Financial Position

The company has a current ratio of 15.28, with a Debt / Equity ratio of 0.04.

Current Ratio	15.28
Quick Ratio	15.14
Debt / Equity	0.04
Debt / EBITDA	n/a
Debt / FCF	-0.42
Interest Coverage	-36.94

Financial Efficiency

Return on equity (ROE) is -4.41% and return on invested capital (ROIC) is -3.98%.

Return on Equity (ROE)	-4.41%
Return on Assets (ROA)	-3.76%
Return on Capital (ROIC)	-3.98%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.01
Inventory Turnover	1.34

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -38.98% in the last 52 weeks. The beta is 0.73, so Gongwin Biopharm Holdings's price volatility has been lower than the market average.

Beta (5Y)	0.73
52-Week Price Change	-38.98%
50-Day Moving Average	111.09
200-Day Moving Average	149.02
Relative Strength Index (RSI)	53.15
Average Volume (20 Days)	160,813

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Gongwin Biopharm Holdings had revenue of TWD 31.76 million and -102.96 million in losses. Loss per share was -0.88.

Revenue	31.76M
Gross Profit	17.97M
Operating Income	-151.85M
Pretax Income	-100.75M
Net Income	-102.96M
EBITDA	-141.33M
EBIT	-151.85M
Loss Per Share	-0.88

Full Income Statement

Balance Sheet

The company has 2.43 billion in cash and 117.03 million in debt, giving a net cash position of 2.32 billion or 18.17 per share.

Cash & Cash Equivalents	2.43B
Total Debt	117.03M
Net Cash	2.32B
Net Cash Per Share	18.17
Equity (Book Value)	3.19B
Book Value Per Share	26.07
Working Capital	2.33B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -81.47 million and capital expenditures -199.92 million, giving a free cash flow of -281.38 million.

Operating Cash Flow	-81.47M
Capital Expenditures	-199.92M
Free Cash Flow	-281.38M
FCF Per Share	-2.21

Full Cash Flow Statement

Margins

Gross Margin	56.58%
Operating Margin	-478.06%
Pretax Margin	-317.17%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	-885.86%

Dividends & Yields

Gongwin Biopharm Holdings does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-3.98%
Shareholder Yield	-3.98%
Earnings Yield	-0.78%
FCF Yield	-1.95%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	n/a